pharmaceutical industry

Biocat, the organisation responsible for coordinating and promoting the life sciences sector in Catalonia, presented the 2013 Biocat report in Barcelona. Since its creation in 2006, by the Catalan Government and the Barcelona City Council, Biocat has sought to consolidate the life sciences sector by bringing together researchers, companies and other professionals in the field of biotechnology and biomedecine from Catalonia and other countries in the world. With 65 % of its biotechnology, pharmaceutical and medical products sold on the international market, the Catalan ‘Bioregion’(biocluster) is amongst the leaders in the sector. The cluster is currently made of 512 companies, meaning twice as many as in 2000, 56 research centers dedicated to life sciences or related disciplines, 17 university hospitals and 11 universities offering training in biosciences. It also relies on numerous other technology poles. This year’s report stressed the significant increase in private funding for the Catalan BioRegion over the last 4 years (€ 5.7 million to € 25.6 million) while highlighting the drop in public aid.

The company, which is based in Greater Barcelona, is the world’s third leader in blood derivatives pharmaceutical products. Last year, it bought out its main competitor in the United States, Talecris. Grífols had a €2.62 billion turnover in 2012 and almost doubled its sales compared to the 2011 figures. The company’s net profit last year quadruples that of 2011. The good results are due to a significant reduction in debt levels and Grífols’ penetration into the United States market. Besides, this week it announced it bought for €37 million the 60% of Progenika Biopharma’s capital, a Basque biotechnology company specialised in the design of diagnostic tests.

Catalonia is the second Autonomous Community, behind Galicia, where drug expenditure decreased the most in November. The austerity measures approved by the Catalan and the Spanish Governments to reduce drug expenditure are behind the significant drops in spending in Catalonia and the rest of Spain over the last few months. Pharmaceutical expenditure dropped by 13.11% over the first 11 months of 2012. Besides, the number of drug prescriptions issued in November in Catalonia decreased by 21.27% compared to a year ago.

Chemists in Catalonia had called to go on strike on Thursday because the Catalan Government owed them two payments for publicly funded drugs. According to the Catalan Government, the payments were delayed as they depended on receiving the funds from the Spanish Government’s Liquidity Fund. The Spanish Government announced this week it was transferring €99 million to the Catalan Government to pay the chemists. However, on Wednesday the chemists decided to maintain Thursday’s strike “as a warning signal” for the uncertainty on future payments and because they have not received yet the promised payment.

The expansion to Brazil is part of the company’s international development plan, which aims to start operations in Latin America, the Middle East and Asia. The company hopes to replicate its successful European business model overseas and has started with the opening of new offices in São Paulo. Galenicum, a developer of generic medicines, is based in Barcelona and produced a turnover of €77 million in 2011, a 542% increase in just two years.

Compared to a year ago, the Catalan Healthcare System spent 24.6% less last July than in the same month of 2011. In July 2011, Catalonia spent €143.52 million on pharmaceutical products while it spent €108.10 million last month, when the drug prescription fee began and citizens started to pay a greater share of the cost of prescription drugs. Furthermore, drug prescriptions fell by 20%. In the whole of Spain, pharmaceutical spending also decreased by 24% last July, compared to a year ago.

The Catalan pharmaceutical company Grifols, the third world leader in the production of blood plasma based technologies, has seen its turnover increase by 15% in the first half of 2012 to €1.32 billion. Its net profit for the first half of 2012 was €133.5 million, seven times that of the previous year. The company’s success is attributed to its wide geographical consumer base and the recent purchase of US based Talecris Plasma Resources.